VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+12.8%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$237M
AUM Growth
-$4.18M
(-1.7%)
Cap. Flow
-$15.8M
Cap. Flow
% of AUM
-6.66%
Top 10 Holdings %
Top 10 Hldgs %
7.93%
Holding
416
New
61
Increased
247
Reduced
47
Closed
61
Top Buys
| 1 |
EOG Resources
EOG
|
$2.02M |
| 2 |
PXD
Pioneer Natural Resource Co.
PXD
|
$1.99M |
| 3 |
ConocoPhillips
COP
|
$1.85M |
| 4 |
Imperial Oil
IMO
|
$1.8M |
| 5 |
Reliance Steel & Aluminium
RS
|
$1.76M |
Top Sells
| 1 |
Ryman Hospitality Properties
RHP
|
$2.57M |
| 2 |
Western Midstream Partners
WES
|
$2.52M |
| 3 |
INN
Summit Hotel Properties
INN
|
$2.43M |
| 4 |
Brookfield Renewable
BEPC
|
$2.38M |
| 5 |
Grupo Aeroportuario del Pacifico
PAC
|
$2.16M |
Sector Composition
| 1 | Healthcare | 30.46% |
| 2 | Real Estate | 18.03% |
| 3 | Energy | 13.68% |
| 4 | Materials | 11.34% |
| 5 | Utilities | 10.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
Y-mAbs Therapeutics
YMAB
$389M
| $363K | 0.15% |
11,993
+331
| +3% | +$10K |
|
|
JRO
202
DELISTED
Nuveen Floating Rate Income Opportunty Fund
JRO
| $361K | 0.15% |
37,860
+1,257
| +3% | +$12K |
|
203
BioCryst Pharmaceuticals
BCRX
$1.74B
| $359K | 0.15% |
35,331
+624
| +2% | +$6.34K |
|
204
Nuveen Floating Rate Income Fund
JFR
$1.13B
| $359K | 0.15% |
37,172
+1,262
| +4% | +$12.2K |
|
205
Quince Therapeutics
QNCX
$85.9M
| $359K | 0.15% |
9,977
+173
| +2% | +$6.23K |
|
206
MEI Pharma
MEIP
$140M
| $356K | 0.15% |
5,186
+91
| +2% | +$6.25K |
|
|
MRNS
207
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $355K | 0.15% |
22,912
+409
| +2% | +$6.34K |
|
208
Alaunos Therapeutics
TCRT
$4.27M
| $350K | 0.15% |
648
+12
| +2% | +$6.48K |
|
209
Immatics
IMTX
$695M
| $348K | 0.15% |
31,058
+550
| +2% | +$6.16K |
|
|
ITOS
210
DELISTED
iTeos Therapeutics
ITOS
| $345K | 0.15% |
10,092
+176
| +2% | +$6.02K |
|
|
DCF
211
DELISTED
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc.
DCF
| $343K | 0.14% |
36,617
+1,578
| +5% | +$14.8K |
|
212
Arvinas
ARVN
$559M
| $340K | 0.14% |
5,151
+98
| +2% | +$6.47K |
|
213
Annexon
ANNX
$236M
| $339K | 0.14% |
12,171
+213
| +2% | +$5.93K |
|
214
Celldex Therapeutics
CLDX
$1.51B
| $339K | 0.14% |
16,464
+290
| +2% | +$5.97K |
|
|
AFMD
215
DELISTED
Affimed
AFMD
| $338K | 0.14% |
4,271
+74
| +2% | +$5.86K |
|
|
EFR
216
Eaton Vance Senior Floating-Rate Fund
EFR
$344M
| $335K | 0.14% |
24,329
+3,527
| +17% | +$48.6K |
|
|
IMGN
217
DELISTED
Immunogen Inc
IMGN
| $335K | 0.14% |
41,359
+724
| +2% | +$5.86K |
|
218
Crinetics Pharmaceuticals
CRNX
$3.23B
| $334K | 0.14% |
21,882
+395
| +2% | +$6.03K |
|
219
MeiraGTx Holdings
MGTX
$621M
| $334K | 0.14% |
23,179
+416
| +2% | +$5.99K |
|
|
SRNE
220
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $332K | 0.14% |
40,100
+713
| +2% | +$5.9K |
|
|
PHD
221
Pioneer Floating Rate Fund
PHD
$123M
| $331K | 0.14% |
28,849
+4,059
| +16% | +$46.6K |
|
222
TG Therapeutics
TGTX
$5.06B
| $331K | 0.14% |
6,868
+125
| +2% | +$6.02K |
|
223
Cytokinetics
CYTK
$5.95B
| $329K | 0.14% |
14,136
+247
| +2% | +$5.75K |
|
224
Verastem
VSTM
$650M
| $327K | 0.14% |
11,025
+195
| +2% | +$5.78K |
|
225
Kezar Life Sciences
KZR
$28M
| $324K | 0.14% |
5,431
+96
| +2% | +$5.73K |
|